Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VK 0214

Next Previous
Search
Drug Profile

VK 0214

Alternative Names: MB-10866; VK 0214

Latest Information Update: 09 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Metabasis Therapeutics
  • Developer Viking Therapeutics
  • Class Acetates; Benzene derivatives; Phosphorus compounds; Small molecules
  • Mechanism of Action Thyroid hormone receptor beta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adrenoleucodystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Adrenoleucodystrophy

Most Recent Events

  • 08 Nov 2024 Viking Therapeutics completes the phase I trial in Adrenoleucodystrophy in USA, France, Germany, Italy and United Kingdom (PO) after April 2022 (NCT04973657)
  • 09 Oct 2024 Efficacy and adverse events data from a phase-I clinical trials in Adrenoleucodystrophy released by Viking Therapeutics
  • 28 Aug 2024 VK 0214 is still in phase I development in Adrenoleucodystrophy in United Kingdom (PO, Capsule) (NCT04973657)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top